Navigation Links
GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
Date:10/15/2007

body. This is important because it means that surgery is rarely used as a treatment option. Chemotherapy is the most common treatment for SCLC. Although SCLC is often responsive to first-line treatments, patients may relapse.

SCLC is most common in current or past smokers, but can also be caused by environmental risk factors such as exposure to radon and air pollution. About 15% of patients with lung cancer have SCLC, a fast-growing form of the disease.

About HYCAMTIN(R) Capsules

HYCAMTIN capsules belong to a class of drugs known as topoisomerase I (topo-I) inhibitors. Topo-I is a naturally produced protein essential for cell division in both normal and cancer cells. Interaction between topo-I and HYCAMTIN capsules results in permanent damage to the cell's genetic material and the death of dividing cells. Registration dossiers for HYCAMTIN capsules have been submitted in Europe, Canada and other markets around the world.

Important Safety Information

HYCAMTIN capsules can suppress the body's ability to produce disease fighting white blood cells, a condition known as neutropenia. In addition, the amount of clotting cells can decrease (thrombocytopenia). Generally, HYCAMTIN capsules have a mild to moderate non-hematologic toxicity profile. Other common side effects include nausea, vomiting, diarrhea and hair loss (alopecia).

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Point of Care Strep Tests Speed Treatment, Lower Costs
6. Rapid HIV Testing Increases Possibility of Treatment
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... HERZELIYA, Israel, September 30 ... in an investment round led by 7 Health,Ventures. ... in the round as well. , ... optical guidance systems used,in Computer Tomography (CT), fluoroscopy ...
... Ill., Sept. 30 Life Spine announced today that ... 510(k) marketing approval to the SENTINEL Occipito-Cervico-Thoracic (OCT) System. ... and promotes fusion from the occiput to thoracic spine, ... procedures. Polyaxial screws are available in multiple diameters and ...
Cached Medicine Technology:
(Date:8/28/2014)... (PRWEB) August 29, 2014 ... brings pharmaceutical industry precision to the development and ... approval for its primary location in Sarasota County. ... decisively with a total commitment to attracting new ... to creating," says David Wright, President and CEO ...
(Date:8/28/2014)... Arizona (PRWEB) August 28, 2014 When ... and long-time friend of Mark Brnovich, was asked ... the Republican nomination for the Attorney General seat in ... He quickly gathered the support of Cardinal Hall of ... Arizona Cardinals Derek Kennard and Mark Walczak. Green, Kennard ...
(Date:8/28/2014)... 2014 New Energy Works Timberframe plans ... around the country to Log & Timber Home Shows ... The New Energy Works team will invite the shows’ ... and build expertise, project images, and their new 2015 ... Energy Works’ Mid-West Representative, will present “A fun-fill odyssey: ...
(Date:8/28/2014)... A 42-year-old investment banker arrives at the emergency ... tremor. He drinks alcohol every dayoften at business ... his health, he decided to quit drinking and ... to emergency. , It,s a common scenario in ... excessive alcohol consumption and develops withdrawal. , Withdrawal ...
(Date:8/28/2014)... On August 21, the Mesothelioma Applied ... featuring the organization’s audited financial information, as well as ... the report, in 2013, the Meso Foundation spent 86 ... on fundraising and administration. , “The Meso Foundation ... Foundation’s chief executive officer, Melinda Kotzian. , “As a ...
Breaking Medicine News(10 mins):Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... Calif., April 10, 2008 IPC,The Hospitalist Company, Inc. ... focused on the delivery of hospitalist medicine services,announced today ... 2008,ended March 31, 2008 on Wednesday, May 14, 2008, ... review the results will begin at 5:00 p.m. ET,(2:00 ...
... Partners With Asthma and Allergy Foundation of America To ... Combat Allergens in the Bedroom, ... with the Asthma and Allergy Foundation of America,(AAFA) to educate consumers ... spend one third of their lives: the bedroom., "Many people ...
... Brings Unique Opportunity to Emerging Hip-Hop ... Talent, ... & Gamble,s TAG brand announce the formation of a new,hip-hop record label, TAG ... act as president of the New York-based,venture. As president, Dupri will set the ...
... and OTTAWA, April 10 Natural,Nutrition, Inc. (OTC ... launch its new health and nutritional information portal,iNutrition.com, ... to consumers relating to a healthy lifestyle, nutrition ... as a trusted,healthcare and information resource for our ...
... One Consumer Request, PLANO, Texas, April 10 ... of Pinch of Salt, a,low-sodium version of some of ... chips, Fritos corn chips and Ruffles potato chips.,While Frito-Lay ... with,-- for instance Lay,s Classic potato chips contain 180 ...
... , CamelBak is pleased to announce that our ... by the end of April, 2008. First to,market in ... color, CamelBak will have an entirely BPA-free product line ... Better,Bottle(TM) with Bite Valve, the CamelBak Better Bottle(TM) with ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. to Report First Quarter 2008 Financial Results 2Health News:Leave Bedroom Allergens High and Dry This Spring! 2Health News:Leave Bedroom Allergens High and Dry This Spring! 3Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 2Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 3Health News:Natural Nutrition to Launch iNutrition.com 2Health News:Frito-Lay Launches Low Sodium Versions of its Top Selling Snack Chips 2
Assay for Anti-HTLV-I and Anti-HTLV-II...
... assays for the blood screening market. We have ... in contract funding from the National Heart, Lung, ... develop the Procleix WNV Assay. This assay was ... under an Investigational New Drug Application (IND) on ...
Test for Anti-HBc for use on the Abbott Prism...
... BenchMark XT® the only fully automated ... you need to expand your test ... your slide turnaround time. All with ... how to use the BenchMark XT® ...
Medicine Products: